Article
Infectious Diseases
Welder Zamoner, Karina Zanchetta Cardoso Eid, Lais Maria Bellaver de Almeida, Isabella Goncalves Pierri, Adriano dos Santos, Andre Luis Balbi, Daniela Ponce
Summary: This study suggests that higher serum concentrations of vancomycin are associated with acute kidney injury in critically ill septic patients, preceding the diagnosis by at least 48 hours. It can be a useful monitoring tool when AUC cannot be used.
Article
Immunology
Thomas P. Lodise, George Drusano
Summary: AUC-guided monitoring for vancomycin is recommended for patients with serious MRSA infections to minimize the risk of VA-AKI while maintaining efficacy. Data show that AUC drives the risk of VA-AKI, and AUC monitoring can help reduce its occurrence.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Pharmacology & Pharmacy
Durval Sampaio de Souza Garms, Karina Zanchetta Cardoso Eid, Emmanuel A. Burdmann, Lia Junqueira Marcal, Leila Antonangelo, Adriano dos Santos, Daniela Ponce
Summary: Acute kidney injury (AKI) related to vancomycin is frequent in hospitalized patients, with age, plasmatic vancomycin concentrations, and urinary NGAL identified as predictors of AKI related to vancomycin use. Plasmatic vancomycin concentrations and urinary NGAL were predictors of AKI diagnosis within the next 5 days, while urinary biomarkers of cell cycle arrest TIMP-2 and IGFBP-7, along with the duration of vancomycin use, were associated with non-recovery of kidney function at hospital discharge.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Jee Yun Kim, Kyun Young Kim, Jeong Yee, Hye Sun Gwak
Summary: This study aimed to construct a risk scoring system for vancomycin-associated acute kidney injury (AKI). A retrospective review of medical records was conducted and potential risk factors were identified. Machine learning methods were used to predict the occurrence of AKI. The developed scoring system showed good predictive performance and can be applied in clinical settings where multiple nephrotoxic agents are used with vancomycin therapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Infectious Diseases
Abdulmajeed M. Alshehri, Mohammed Y. Alzahrani, Mohammed A. Abujamal, Mariam H. Abdalla, Shuroug A. Alowais, Osamah M. Alfayez, Majed S. Alyami, Abdulaali R. Almutairi, Omar A. Almohammed
Summary: The study found that combining vancomycin with piperacillin-tazobactam increases the risk of acute kidney injury in adult patients, while combining it with meropenem shows no significant difference. Clinicians should be cautious in using V + PT, especially in patients at high risk of AKI.
Article
Medicine, General & Internal
Sang-Mi Kim, Hyun-Seung Lee, Min-Ji Kim, Hyung-Doo Park, Soo-Youn Lee
Summary: The study evaluated the diagnostic value of nine serum biomarkers for vancomycin-induced kidney injury (VIKI) and found that TFF3, cystatin C, TNF-R1, and osteopontin had excellent diagnostic value for VIKI and showed a strong negative correlation with estimated glomerular filtration rate.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Microbiology
Heather D'Amico, Katie L. Wallace, Donna Burgess, David S. Burgess, Sarah Cotner, Ryan Mynatt, Nannan Li, Arnold Stromberg, Jeremy VanHoose
Summary: This study found that monitoring vancomycin treatment using AUC(24) was associated with a decreased risk of acute kidney injury in obese patients.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Urology & Nephrology
Ioannis Bellos, Vasilios Pergialiotis, Despina N. Perrea
Summary: This study analyzed biopsy-proven cases of vancomycin nephrotoxicity and found that acute tubulointerstitial nephritis was a major histological pattern associated with a significantly higher risk of permanent renal dysfunction. Fibrosis and tubulitis played important roles in renal prognosis.
INTERNATIONAL UROLOGY AND NEPHROLOGY
(2022)
Article
Pharmacology & Pharmacy
Graziella Gasparotto Baiocco, Stephanie Greiner, Mario Borges Rosa, Cecilia Dias Flores, Helena M. T. Barros
Summary: This study aimed to evaluate the incidence of acute kidney injury (AKI) in patients receiving vancomycin before and after the implementation of an institutional protocol for vancomycin administration in a public tertiary hospital in southern Brazil. The results showed a significant reduction in AKI incidence after the implementation of the institutional protocol for vancomycin administration.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Gwendolyn M. Pais, Sylwia Marianski, Kimberly Valdez, Renz Paulo Melicor, Jiajun Liu, Roxane Rohani, Jack Chang, Steven Y. C. Tong, Joshua S. Davis, Marc H. Scheetz
Summary: The study found that combining flucloxacillin with vancomycin in a rat model caused more severe kidney injury compared to vancomycin alone. Conversely, the combination of vancomycin with imipenem-cilastatin had a nephroprotective effect.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Article
Critical Care Medicine
Todd A. Miano, Sean Hennessy, Wei Yang, Thomas G. Dunn, Ariel R. Weisman, Oluwatosin Oniyide, Roseline S. Agyekum, Alexandra P. Turner, Caroline A. G. Ittner, Brian J. Anderson, F. Perry Wilson, Raymond Townsend, John P. Reilly, Heather M. Giannini, Christopher Cosgriff, Tiffanie K. Jones, Nuala J. Meyer, Michael G. S. Shashaty
Summary: The study suggests that the combination of vancomycin and piperacillin-tazobactam may increase the risk of acute kidney injury, but does not significantly affect alternative kidney biomarkers, dialysis, or mortality. This supports the hypothesis that the effects of vancomycin and piperacillin-tazobactam on creatinine represent pseudotoxicity.
INTENSIVE CARE MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Medha D. Joshi, Paulina Iacoban, Marc H. Scheetz
Summary: This study successfully encapsulated vancomycin in polyethylene glycol-coated liposomes (PEG-VANCO-lipo) and compared its effects with standard vancomycin. The results showed that PEG-VANCO-lipo resulted in lower levels of kidney injury, as indicated by decreased levels of KIM-1 in urine and reduced plasma vancomycin concentration. These findings suggest that PEG-VANCO-lipo has a high potential to decrease the nephrotoxicity of vancomycin clinically.
Article
Pharmacology & Pharmacy
Hanouf A. Aljohani, Hadeel A. Alharbi, Sarah A. Basurrah, Sarah A. Alamoudi, Abrar K. Thabit
Summary: A retrospective cohort study on hospitalized patients found that the combination of vancomycin and proton pump inhibitors did not increase the risk of acute kidney injury. However, monitoring kidney function is still recommended when using either drug.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
(2022)
Article
Medicine, General & Internal
R. F. Tookhi, N. A. Kabli, M. A. Huntul, A. K. Thabit
Summary: This study aimed to evaluate the rate of acute kidney injury (AKI) in patients receiving either VAN with TZP or VAN with MEM, finding a higher AKI rate but non-significant difference in the VAN-MEM group compared to the VAN-TZP group. In-hospital mortality was higher in the VAN-MEM group, possibly due to a higher percentage of critically ill patients in that group.
INTERNAL AND EMERGENCY MEDICINE
(2021)
Article
Infectious Diseases
Maria H. Rigatto, Pedro Bergo, Giulia Baldissera, Eduarda Beck, Leonardo David, Lucas Santoro, Andressa Barros, Rafael Zanin, Joao I. Budelon Goncalves, Diego Falci, Wolnei Caumo, Alexandre P. Zavascki
Summary: This study compared the effect of melatonin versus placebo on the incidence of acute kidney injury (AKI) in patients treated with polymyxin B. The results showed that initiating melatonin within the first 48 hours of therapy did not reduce the risk of AKI in patients treated with polymyxin B.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Pharmacology & Pharmacy
Sean N. Avedissian, Nathaniel J. Rhodes, Tien M. H. Ng, Adupa P. Rao, Paul M. Beringer
Article
Multidisciplinary Sciences
Virginia Basso, Dat Q. Tran, Justin B. Schaal, Patti Tran, Yoshihiro Eriguchi, Diana Ngole, Anthony E. Cabebe, A. Young Park, Paul M. Beringer, Andre J. Ouellette, Michael E. Selsted
SCIENTIFIC REPORTS
(2019)
Article
Oncology
Weijun Wang, Haiping He, Nagore Marin-Ramos, Shan Zeng, Steven D. Swenson, Hee-Yeon Cho, Jie Fu, Paul M. Beringer, Josh Neman, Ligang Chen, Axel H. Schonthal, Thomas C. Chen
Summary: NEO100 facilitates brain tumor entry of trastuzumab and T-DM1, significantly enhancing therapeutic efficacy and increasing antibody-dependent immune cell recruitment.
Article
Chemistry, Multidisciplinary
Rajasekaran Ganesan, Mansour A. Dughbaj, Lisa Ramirez, Steven Beringer, Teshome L. Aboye, Alexander Shekhtman, Paul M. Beringer, Julio A. Camarero
Summary: This study reports the development of a novel engineered cyclotide with effective broad-spectrum antibacterial activity against several ESKAPE bacterial strains and clinical isolates. The most active antibacterial cyclotide was extremely stable in serum, showed little hemolytic activity, and provided protection in vivo in a murine model of P. aeruginosa peritonitis. These results highlight the potential of the cyclotide scaffold for the development of novel antimicrobial therapeutic leads for the treatment of bacteremia.
CHEMISTRY-A EUROPEAN JOURNAL
(2021)
Correction
Oncology
Weijun Wang, Haiping He, Nagore I. Marin-Ramos, Shan Zeng, Steven D. Swenson, Hee-Yeon Cho, Jie Fu, Paul M. Beringer, Josh Neman, Ligang Chen, Axel H. Schonthal, Thomas C. Chen
Article
Microbiology
A. Young J. Park, Dat Q. Tran, Justin B. Schaal, Mengxi Wang, Michael E. Selsted, Paul M. Beringer
Summary: This study characterized the preclinical pharmacokinetics and safety of intravenous RTD-1. The results showed extensive tissue distribution and excellent safety profile for RTD-1, supporting its clinical investigation for the treatment of COVID-19 or other pulmonary inflammatory diseases.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Chemistry, Organic
Dipankar Chaudhuri, Rajasekaran Ganesan, Alicia Vogelaar, Mansour A. Dughbaj, Paul M. Beringer, Julio A. Camarero
Summary: A new epimerization-free approach for the Fmoc-based synthesis of murepavadin using intramolecular native chemical ligation and desulfurization reaction has been developed, resulting in a high yield of bioactive murepavadin in two steps. The synthetic peptide antibiotic showed potent activity against different clinical isolates of P. aeruginosa. This approach can be easily adapted for the production of murepavadin analogues and other backbone-cyclized peptides.
JOURNAL OF ORGANIC CHEMISTRY
(2021)
Article
Pharmacology & Pharmacy
Eunjin Hong, Lisa M. Almond, Peter S. Chung, Adupa P. Rao, Paul M. Beringer
Summary: Cystic fibrosis patients are at higher risk following COVID-19 infection, and it is crucial to manage the drug-drug interaction between CFTR modulating therapies and COVID-19 treatments. This study used a pharmacokinetic modeling approach to evaluate the interaction and proposed a treatment regimen to minimize its impact.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Microbiology
E. Hong, L. M. Almond, P. S. Chung, A. P. Rao, P. M. Beringer
Summary: This study evaluates the drug-drug interactions between elexacaftor, tezacaftor, and ivacaftor and the NTM treatment drugs in people with cystic fibrosis. Physiologically based pharmacokinetic modeling is used to predict and adjust the dosing regimens, ensuring effective treatment. The study provides evidence for the use of NTM treatment drugs in conjunction with appropriately adjusted doses of cystic fibrosis therapies.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Review
Biochemistry & Molecular Biology
Eunjin Hong, Alan Shi, Paul Beringer
Summary: Cystic fibrosis (CF) is a disease characterized by mucus accumulation, and CFTR modulators significantly improve lung function and nutritional status. However, they can interact with certain enzymes and transporters, leading to potential drug-drug interactions (DDI).
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
(2023)
Article
Pharmacology & Pharmacy
Eunjin Hong, Regina Li, Alan Shi, Lisa M. Almond, Joshua Wang, Amin Z. Khudari, Soumar Haddad, Sarkis Sislyan, Marissa Angelich, Peter S. Chung, Adupa P. Rao, Paul M. Beringer
Summary: This study provides evidence that reduced doses of Elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis patients who have experienced adverse effects may be effective. The physiologically based pharmacokinetic (PBPK) models enable exploration of a mechanistic basis for this finding by simulating target tissue concentrations of ETI that can be compared with drug efficacy in vitro.
Article
Pharmacology & Pharmacy
Eunjin Hong, Eugeniu Carmanov, Alan Shi, Peter S. Chung, Adupa P. Rao, Kevin Forrester, Paul M. Beringer
Summary: ETI treatment has potential benefits for lung transplant recipients, but the use of ivacaftor as a part of the treatment may increase the risk of elevated systemic exposure to tacrolimus. This study aims to determine the impact of ETI on tacrolimus exposure and develop an appropriate dosing regimen to manage this drug-drug interaction.
Article
Infectious Diseases
Mansour A. Dughbaj, Jordanna G. Jayne, A. Young J. Park, Timothy J. Bensman, Marquerita Algorri, Andre J. Ouellette, Michael E. Selsted, Paul M. Beringer
Summary: RTD-1 exhibited potent anti-inflammatory activity in a murine model of chronic P. aeruginosa lung infection, reducing lung white blood cell counts and proinflammatory gene expression, particularly inflammasome-related genes. This immunomodulatory peptide may be a promising therapeutic for CF-associated lung disease.
Meeting Abstract
Pediatrics
E. Hong, A. P. Rao, P. Beringer
PEDIATRIC PULMONOLOGY
(2020)
Meeting Abstract
Pediatrics
J. Wang, D. Benitez, P. Beringer, A. Rao
PEDIATRIC PULMONOLOGY
(2019)